Pain is the chief morbidity that severely decreases the quality of life of patients who suffer from sickle cell disease (SCD). These patients experience acute pain which may result from peripheral vaso-occlusion, tissue ischemia and inflammation. Many also suffer from chronic pain that may result from chronic inflammation and dysregulated neuronal firing and connectivity within the peripheral and central nervous system. Dr. Cheryl Stucky, Director of the Neuroscience Doctoral Program at the Medical College of Wisconsin, will discuss the work her laboratory has done to interrogate the peripheral mechanisms underlying sickle cell pain by using rodent models of SCD in combination with electrophysiological, cellular and behavioral assays. She will also discuss her work with Dr. Amanda Brandow, Associate Professor at Medical College of Wisconsin, to investigate phenotypes and mechanisms of pain in patients with sickle cell disease.
Join AnaBios for our latest pain research webinar, presented by Dr. Laura Stone, associate professor at McGill University in Montreal, Quebec. Dr. Stone will present findings on low back pain that involve both human and animal models. She’ll discuss dysregulation of Nerve Growth Factor (NGF) and immune mediators in human cerebrospinal fluid and intervertebral discs obtained from patients vs. controls. She’ll also explore proof-of-concept studies targeting these mechanisms in a pre-clinical model of low back pain, and will present human and animal study data implicating epigenetic mechanisms in chronic pain. The challenges and rewards of translational research will be highlighted throughout the presentation.
There is an urgent need for new therapeutics to address chronic pain, which affects approximately 20% of U.S. adults. This 60-minute webinar, presented by Dr. Ted Price, neuroscience professor at the University of Texas at Dallas, focused on utilizing human dorsal root ganglia (DRG) samples from patients and organ donors to gain new insight into the molecular mechanisms that may underlie chronic pain. Dr. Price also discusses integrating sensory neuronal transcriptomics with other datasets more widely available from patients to better understand how the nervous system interacts with diseased tissues to promote chronic pain. This unique approach offers opportunities to thoroughly vet pain targets without relying heavily on pre-clinical models.
Respiratory complications are the primary cause of hospitalization in COVID-19 patients, with complex interactions between the virus, lung epithelial cells and immune cells leading to severe acute respiratory syndrome. As scientists and researchers race to develop novel therapeutics to fight the virus, it is important to have research tools available that provide highly translatable data, therefore accelerating the path to clinical studies. The precision cut lung slice (PCLS) discussed in this webinar is an advanced paradigm for translational lung research. In this hour-long webinar, Harvard professors Dr. Rama Krishnan and Dr. Joe Brain will discuss how PCLS is an effective preparation for advancing lung-related physiology and drug discovery studies. In PCLS, the morphological organization slices of cells, matrix, airways and vessels are nearly identical to that of in vivo lung. Additional practical advantages of PCLS includes its ease of preparation, ease of storage (via cryopreservation), suitability for high-resolution microscopy imaging and inclusion of many species, particularly human. Given its versatility and unique advantages, PCLS are readily customized to applications in physiology, toxicology, immunology and infectious diseases.
Dr. Najah Abi-Gerges, Vice President of Research & Development at AnaBios, presents the first research study on the impact of late sodium current (INa,L) modulation on the excitation-contraction coupling in adult human primary cardiomyocytes in this new webinar. This data demonstrates that these human cardiomyocytes (1) express functional INa,L, (2) can differentiate INa,L facilitators from inhibitors and (3) provide valuable assessment of novel INa,L inhibitors to prevent the occurrence of drug-induced pro-arrhythmia and aid in the development of dysrhythmia medications. In addition, this 60-minute webinar presents information about AnaBios’ unique human tissue platform and electrophysiological and imaging capabilities. We are the only CRO that procures ethically consented human organs from a vast donor network in the United States. We also perform physiological assays using the cells and tissues from these organs. Learn about the different types of human tissue and cell-based assays and how translational assays are impacting preclinical drug discovery.
Dr. Michael Hildebrand, associate professor of neuroscience at Carleton University, highlights his recent work aimed at bridging the translational divide between target identification in rodent models of chronic pain and direct clinical testing of candidate compounds in humans. His research team has developed a novel human spinal cord tissue model of pathological pain that parallels rodent in vivo and ex vivo pain models. Using these complementary approaches, Dr. Hildebrand and his team are identifying molecular determinants of spinal cord hyperexcitability that are conserved across species, and thus may inform the rational development of more effective therapeutics for chronic pain.
- Pro-arrhythmia & contractility risk
- Human primary atrial cells in atrial fibrillation drug discovery
- Advancing the understanding of heart failure and new therapies with human primary ventricular myocytes and tissues